Federal Judge Rules Novartis Cannot Block Generic Entresto Launch by MSN Pharmaceuticals Until Late 2026

A federal judge in Delaware has ruled that Novartis cannot prevent MSN Pharmaceuticals from introducing a generic version of its heart failure drug, Entresto, in the United States until late 2026. The decision marks a significant development in the ongoing legal dispute over the patent rights for the blockbuster medication.

The ruling, issued on Friday, denies Novartis’ attempt to extend its exclusivity on Entresto by blocking MSN Pharmaceuticals’ plans to launch a lower-cost generic alternative. Entresto is one of Novartis’ top-selling drugs and is widely prescribed for patients with chronic heart failure. The case centers around patent claims made by Novartis, which sought to delay competition from generics. However, the court found that MSN Pharmaceuticals could proceed with its plans to introduce a generic version before the end of 2026. This decision could have implications for both companies and potentially impact pricing and availability of the drug in the U.S. market.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: July 15, 2025

Author

Mark Chiang